Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets
Last month
Boehringer Ingelheim’s late-stage data for lung disease candidate underwhelm some analysts
Last month
Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff
Last month
People
Cell/Gene Tx
Intellia's CRISPR therapy likely causes 'permanent' gene knockdown in ATTR amyloidosis
Last month
Pharma
Cell/Gene Tx
David Liu, Sam Sternberg unveil new way to insert big genes in human cells
Last month
Cell/Gene Tx
Apnimed posts first set of Phase 3 sleep apnea results, aims for approval filing in 2026
Last month
Startups
Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers
Last month
FDA+
Lower attendance at cell and gene therapy conference mirrors challenged industry
Last month
Cell/Gene Tx
In three patients, Rocket’s second heart gene therapy shows promise
Last month
Cell/Gene Tx
RFK Jr. adopts new chikungunya vaccine guidance; other recommendations remain under review
Last month
Pharma
FDA+
The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease
Last month
Cell/Gene Tx
In Focus
Advocacy groups and experts call for decade-long ban on germline editing
Last month
Cell/Gene Tx
Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs
Last month
Cytokinetics gets an 'incremental' win for delayed heart drug
Last month
TIGIT graveyard expands as GSK drops late-stage asset with iTeos
Last month
Vir’s hep B disappointment, Ipsen's new Iqirvo data, plus more from #EASL25
Last month
Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovy
Last month
Trump says he'll sign order on 'most favored nation' drug price plans Monday
Last month
Pharma
Revolution’s KRAS drugs appear competitive in several lung cancer settings
2 months ago
Corvus' early-phase atopic dermatitis data prompt stock rally
2 months ago
'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis
2 months ago
Cell/Gene Tx
In Focus
Lantheus culls late-stage Lilly-partnered prostate cancer radioligand
2 months ago
Gilead reveals plans to put another $11B into US manufacturing
2 months ago
Pharma
Manufacturing
Theriva’s oncolytic virus succeeds in pancreatic cancer study, but stock falls
2 months ago
First page
Previous page
4
5
6
7
8
9
10
Next page
Last page